BCE: Q1 Earnings Insights

BCE (NYSE:BCE) reported its Q1 earnings results on Thursday, May 4, 2023 at 07:00 AM. Here’s what investors…

BCE (NYSE:BCE) reported its Q1 earnings results on Thursday, May 4, 2023 at 07:00 AM.

Here’s what investors need to know about the announcement.

Earnings

BCE beat estimated earnings by 10.53%, reporting an EPS of $0.63 versus an estimate of $0.57.

Revenue was down $139.00 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.01 which was followed by a 0.07% drop in the share price the next day.

Here’s a look at BCE’s past performance:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate 0.54 0.62 0.65 0.62
EPS Actual 0.53 0.67 0.68 0.70
Revenue Estimate 4.78B 4.36B 4.58B 4.54B
Revenue Actual 4.79B 4.62B 5.86B 4.62B

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Guidance

BCE management provided guidance for FY 2023, expecting earnings between $2.31 and $2.4 per share.

To track all earnings releases for BCE visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug

Substance use disorder-focused biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) reported on Tuesday second quarter financial results for the three months ended Dec. 31, 2023, The company's primary focus is on developing therapy for acute cannabinoid intoxication (ACI).Total operating expenses in the second quarter of fiscal 2024 were $2.8 million compared with $3.8 million in the same period in fiscal 2023.Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 million, or $(0.15) per share, in the second quarter of fiscal 2023.

ANEB